This company listing is no longer active
SBI Stock Overview
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sourcebio International Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.15 |
| 52 Week High | UK£1.70 |
| 52 Week Low | UK£0.90 |
| Beta | 0.024 |
| 1 Month Change | 2.22% |
| 3 Month Change | -8.00% |
| 1 Year Change | -32.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.75% |
Recent News & Updates
Shareholder Returns
| SBI | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 9.5% | -0.7% | 0.3% |
| 1Y | -32.4% | -3.0% | 0.1% |
Return vs Industry: SBI underperformed the UK Healthcare industry which returned 3.2% over the past year.
Return vs Market: SBI underperformed the UK Market which returned -7.7% over the past year.
Price Volatility
| SBI volatility | |
|---|---|
| SBI Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: SBI has not had significant price volatility in the past 3 months.
Volatility Over Time: SBI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 339 | n/a | sourcebiointernational.com |
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. The company’s services cover histopathology cancer screening and clinical diagnostic services; DNA sequencing services and precision medicine to pharmaceutical and biotechnology companies, academia, contract research organizations, and other research markets; shelf-life testing services and equipment; and COVID-19 antigen PCR testing services. It also manufactures library clones, direct to consumer home test kits, and blood and tissue serological products; and provides employee testing solutions and venue testing.
Sourcebio International Plc Fundamentals Summary
| SBI fundamental statistics | |
|---|---|
| Market cap | UK£85.31m |
| Earnings (TTM) | UK£6.69m |
| Revenue (TTM) | UK£75.61m |
12.7x
P/E Ratio1.1x
P/S RatioIs SBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBI income statement (TTM) | |
|---|---|
| Revenue | UK£75.61m |
| Cost of Revenue | UK£48.44m |
| Gross Profit | UK£27.18m |
| Other Expenses | UK£20.48m |
| Earnings | UK£6.69m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 35.94% |
| Net Profit Margin | 8.85% |
| Debt/Equity Ratio | 0% |
How did SBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/31 03:44 |
| End of Day Share Price | 2022/12/29 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sourcebio International Plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Doyle | Panmure Liberum |